Results 71 to 80 of about 8,866 (177)

Frontline Therapy in Diffuse Large B‐Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions

European Journal of Haematology, EarlyView.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) remains the most common aggressive lymphoma, representing a biologically heterogeneous disease with diverse clinical behaviors. For more than two decades, R‐CHOP has been the cornerstone of frontline treatment, curing approximately two‐thirds of patients.
Mamdouh Skafi, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Fortunato Morabito, Enrica Antonia Martino, Massimo Gentile   +12 more
wiley   +1 more source

Classification of Platelet‐Activating Anti‐Platelet Factor 4 Disorders

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction The prototypic anti‐platelet factor 4 (PF4) disorder—heparin‐induced thrombocytopenia and thrombosis (HITT)—features immunoglobulin G (IgG) class antibodies that activate platelets, monocytes, and neutrophils in a mainly heparin‐dependent fashion via Fcγ receptor‐dependent cellular activation.
Theodore E. Warkentin
wiley   +1 more source

Tyrphostin AG126 exerts neuroprotection in CNS inflammation by a dual mechanism [PDF]

, 2015
© 2015 Wiley Periodicals, Inc. Acknowledgement Grant sponsor: State of Lower Saxony-Israel Research Cooperation; Grant number: ZN2035; Grant sponsor:German Research Council; Grant number: SFB/TRR43 and FOR1336; Grant sponsor: Parkinson UK; Grant number ...
Akarasereenont, Amedei, Angstwurm, Balachandra, Bermejo, Bettelli, Boucheron, Brenner, Brück, Byrd, Chatterjee, Chiang, Coles, Cossburn, Cuzzocrea, Cuzzocrea, Das Sarma, Doyle, Dugo, Fischer, Fitzner, George, Ghoreschi, Goldmann, Gorina, Gray, Haider, Hanamsagar, Hanisch, Hanisch, Hanisch, Hoffmann, Hong, Horwood, Jaleel, Jefferies, Kahlenberg, Kann, Kawai, Kelly, Khan, Krady, Langer-Gould, Lee, Lehmann, Lehmann-Horn, Lehnardt, Levitzki, Li, Lin, Liu, Liu, Lopez-Talavera, Mangla, Marzocco, Mattsson, Mauro, McDonald, McGeer, Mehta, Mijovic, Mohamed, Moore, Muelas-Serrano, Mukhopadhyay, Murray, Novogrodsky, Perry, Prinz, Raghavan, Ramdas, Regen, Rossum, Ruetten, Sagara, Scheffel, Schmidt, Schweingruber, Simmons, Soltoff, Spitzer, Stewart, Terada, Turpaev, Tönges, Wang, Wang, Weber, Weber, Wüst, Xiao, Zhang, Zorn   +92 more
core   +1 more source

Therapeutic advances in pruritus as a model of personalized medicine

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Recent advances in itch biology reveal that chronic pruritus arises from distinct neuroimmune pathways driven by cytokines, JAK, BTK and GPCRs. Targeted biologics and small molecule inhibitors such as dupilumab, nemolizumab, remibrutinib and JAK inhibitors precisely modulate these pathways, leading to a new era of personalized therapeutics in pruritus.
Kelsey Auyeung, Ramsey Kubofcik, Brian S. Kim   +2 more
wiley   +1 more source

Polo‐like kinases and UV‐induced skin carcinogenesis: What we know and what's next

Photochemistry and Photobiology, EarlyView.
The polo‐like kinase (PLK) family plays distinct and critical roles in the regulation of cell cycle progression, and its dysregulation has been implicated in various cancers. Ultraviolet (UV) radiation is a well‐established environmental factor in the development of skin cancer.
Tanya Jaiswal, Durdana Muntaqua, Gagan Chhabra, Nihal Ahmad   +3 more
wiley   +1 more source

Disease progression more than 6 years after treatment impacts overall survival in mantle cell lymphoma

International Journal of Cancer, Volume 158, Issue 7, Page 1836-1845, 1 April 2026.
What's new? Patients with mantle cell lymphoma showing disease progression within 24 months of primary treatment have worse prognosis than patients with later progression. This population‐based study suggests that although early relapse is especially serious, disease progression more than 6 years after treatment still leads to worse survival than the ...
Sara Ekberg, Ingrid Glimelius, Alexandra Albertsson‐Lindblad, Karin E. Smedby, Mats Jerkeman, Caroline E. Dietrich   +5 more
wiley   +1 more source

HM71224, a selective Bruton’s tyrosine kinase inhibitor, attenuates the development of murine lupus

Arthritis Research & Therapy, 2017
Background Systemic lupus erythematosus (SLE) is associated with B cell hyperactivity, and lupus nephritis (LN), in particular, is promoted by the production of autoantibodies and immune complex deposition.
Yu-Yon Kim, Ki Tae Park, Sun Young Jang, Kyu Hang Lee, Joo-Yun Byun, Kwee Hyun Suh, Young-Mi Lee, Young Hoon Kim, Kwang Woo Hwang   +8 more
doaj   +1 more source

Targetable Vulnerabilities in MYC‐Driven B Cell Lymphomas Resistant to BCR Extinction

Hematological Oncology, Volume 44, Issue 2, March 2026.
ABSTRACT Polatuzumab vedotin, an antibody‐drug conjugate (ADC) targeting the B cell receptor (BCR) signaling subunit CD79B, has recently entered frontline therapy for diffuse large B cell lymphoma (DLBCL) and high‐grade B cell lymphoma (HGBCL), achieving encouraging clinical results. However, MYC‐driven B cell lymphomas, particularly HGBCL with MYC and
Silvia Brambillasca, Nicara Chantal Parr, Adriana Palmeri, Adrian Andronache, Hiroshi Arima, Giovanni Faga’, Brian Leuzzi, Laura Perucho, Michela Robusto, Maurizio Pasi, Federica Mainoldi, Daniele Fancelli, Mario Varasi, Gabriele Varano, Ciro Mercurio, Stefano Casola   +15 more
wiley   +1 more source

Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies

European Journal of Haematology, Volume 116, Issue 3, Page 204-214, March 2026.
ABSTRACT Infections remain a leading cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL), reflecting both intrinsic immune dysfunction and therapy‐related immunosuppression. The pathogenesis of immunodeficiency in CLL is multifactorial: neoplastic B cells impair humoral immunity, T cells are functionally exhausted, and ...
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Massimo Gentile   +10 more
wiley   +1 more source

Drug-perturbation-based stratification of blood cancer [PDF]

, 2018
As new generations of targeted therapies emerge and tumor genome sequencing discovers increasingly comprehensive mutation repertoires, the functional relationships of mutations to tumor phenotypes remain largely unknown.
Dietrich, Sascha, et al, Rossi, Davide, Zenz, Thorsten   +3 more
core   +1 more source